U2AF1 and acute myeloid leukemia: The genes were chosen on the basis of the following criteria: abnormal splicing identified in our study and also in the U2AF1S34F-transgenic mouse CMPs and/or The Cancer Genome Atlas (TCGA) AML patient samples with U2AF1 S34 mutations (18, 23, 26); known biological function (particularly regarding hematopoiesis); and previously described involvement in tumorigenesis.